Synagis (palivizumab) / AbbVie, AstraZeneca, SOBI - LARVOL DELTA

Punicalin targets RSV glycoprotein and fusion protein at non-overlapping sites to prevent viral escape. (PubMed, Cell Rep Med) - "PUN inhibits the evaluated RSV-A and RSV-B strains, including a clinical isolate, and retains activity against strains resistant to ziresovir, ribavirin, nirsevimab, and palivizumab. These regions do not overlap known resistance hotspots. In RSV-infected mice, nebulized PUN provides sustained respiratory exposure, reduces lung viral loads and pathology, and attenuates inflammatory responses."

Journal • Inflammation • Respiratory Diseases • Respiratory Syncytial Virus Infections

Synagis: Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease (clinicaltrials.gov) - P=N/A | N=21 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | N=138 ➔ 21

Enrollment change • Enrollment closed • Respiratory Diseases • Respiratory Syncytial Virus Infections

Farmastock: A collaborative tool for the reuse of high-cost hospital medications in a public healthcare system. (PubMed, Farm Hosp) - "The descriptive findings suggest that Farmastock is a useful and well-valued tool associated with a positive trend in health system sustainability. Beyond the estimated economic impact, it has enabled the utilisation of medicines in exceptional clinical situations, such as palivizumab administration in paediatric patients. Future integration with artificial intelligence and corporate platforms could further amplify its impact."

Journal • Hematological Disorders • Oncology • Pediatrics

Real-World Comparative Effectiveness of Nirsevimab and Palivizumab in High-Risk Infants: A Nationwide Propensity Score-Matched Study (AHA 2026) - "Abstract is embargoed at this time."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Inflammation

RSV Monoclonal Antibody Implementation for At-Risk Infants: Victoria, Australia's 2024 Experience. (PubMed, Health Sci Rep) - "The aim of this study was to monitor the implementation and utilization of nirsevimab and palivizumab in a cohort of infants at increased risk who were program recipients in Victorian hospitals in 2024 and provide evidence and operational context for future programs. Without a national program combining maternal and infant preventatives, hospital-level targeted programs can protect infants at highest risk of severe RSV and reduce admissions; we recommend biopharmaceutical support for these targeted initiatives over large population-wide programs that have not met cost-effectiveness criteria-this 2024 approach informed Australia's 2025 RSV program. Findings will inform ongoing RSV special-risk initiatives."

Journal • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review. (PubMed, Hum Vaccin Immunother) - "Its extended half-life enables season-long protection with a single dose, overcoming key limitations of palivizumab. Comparative 2024-2025 data further suggest greater protection than maternal RSVpreF vaccination. Nirsevimab represents a scalable public-health intervention that can be used alone or complement maternal RSV vaccination, warranting continued surveillance of effectiveness, safety, and viral escape."

Journal • Review • Critical care • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab in the FAERS Database. (PubMed, Kans J Med) - "Nirsevimab and palivizumab demonstrated distinct post-marketing adverse event reporting patterns. Continued post-marketing surveillance is warranted to further characterize the safety profiles of both agents."

Adverse events • Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Adjunctive palivizumab with ribavirin for respiratory syncytial virus infection during the early peri-transplant period in adult allogenic hematopoietic stem cell transplant recipients: Case series. (PubMed, IDCases) - "Adjunctive palivizumab appears to be safe and may be a useful therapeutic option for HSCT recipients with RSV infection during the peri-transplant period. Larger prospective studies are needed to define the optimal role, timing, and route of palivizumab administration in this high-risk population."

Journal • Bone Marrow Transplantation • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

Prevalence and genetic diversity of respiratory syncytial viruses circulating in Bulgaria, 2023-2025. (PubMed, Front Cell Infect Microbiol) - "No substitutions were detected in the F protein antigenic sites of RSV-A (Ø, I-V), including the binding sites for nirsevimab (site Ø), palivizumab (site II), and clesrovimab (site IV). RSV is a leading cause of severe respiratory disease in early childhood and demonstrates substantial genetic diversity among circulating strains. The absence of resistance-associated substitutions in the F protein indicates that currently circulating RSV strains remain susceptible to approved mAbs."

Journal • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey. (PubMed, PLoS One) - "While pediatricians support RSV immunization, knowledge gaps and logistical barriers may hinder early-stage implementation. Optimizing education on RSV immunization will be crucial to improve uptake and prevention strategies."

Journal • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Respiratory syncytial virus outbreaks in healthcare facilities: A review of the literature. (PubMed, Respir Med) - "Elderly patients, residents of LTCFs, and immunocompromised patients should be vaccinated against RSV. Palivizumab prophylaxis should be studied."

Journal • Review • Critical care • Hematological Disorders • Infectious Disease • Oncology • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

Is Prophylaxis With Palivizumab in Very Low Birth Weight Infants Associated With Improved Lung Function at Early School Age? (PubMed, CHEST Pulm) - No abstract available

Journal

Respiratory Syncytial Virus Prophylaxis With Palivizumab Is Not Associated With Improved Lung Function in Infants of Very Low Birth Weight at Early School Age. (PubMed, CHEST Pulm) - "As for FEV1, we did not find any protective effects of palivizumab for other end points or in other risk groups. Palivizumab immunoprophylaxis in VLBWIs is not associated with improved lung function or lower rates of respiratory tract infections in early school-age infants."

Journal • Bronchopulmonary Dysplasia • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Palivizumab for Donor-Derived RSV Infection in an Adult Bilateral Lung Transplant Recipient: A Case Report. (PubMed, Respirol Case Rep) - "We describe a post-operative bilateral lung transplant recipient with donor-derived RSV who developed increasing viral load and progressive respiratory failure despite conventional therapy (enteral ribavirin, methylprednisolone, IVIG) and was ultimately administered palivizumab. The patient was successfully discharged on day 87 and continues to show stable allograft function. This case demonstrates safe use of single dose palivizumab to augment conventional therapy for life-threatening RSV in the profoundly immunocompromised lung transplant recipient."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Transplantation

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein. (PubMed, Vaccines (Basel)) - "The recent approval of two second-generation long-acting mAbs, nirsevimab and clesrovimab, and maternal preF vaccine has fundamentally changed the RSV prevention landscape. Clesrovimab, as the newest agent, currently lacks real-world effectiveness, and both long-acting monoclonals require further confirmatory evidence in high-risk groups. Overall, existing data support that both monoclonals have equivalent efficacy and safety profiles as palivizumab, and choice should be based on cost-effectiveness and local availability, with consideration given to optimal integration of infant immunoprophylaxis alongside maternal RSV vaccination programmes."

Journal • Review • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial. (PubMed, JAMA Pediatr) - P3 | "To evaluate the safety and tolerability of clesrovimab (105 mg) vs palivizumab in RSV season 1 in infants at increased risk for severe RSV disease. These findings support the use of clesrovimab in children who remain at risk for severe RSV disease in their second RSV season. ClinicalTrials.gov Identifier: NCT04938830."

Clinical • Journal • Bronchopulmonary Dysplasia • Cardiovascular • Heart Failure • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Palivizumab for respiratory syncytial virus immunoprophylaxis in high-risk populations in Qatar: a call for action. (PubMed, Expert Rev Anti Infect Ther) - "This paper provides a localized, evidence-based action plan for the healthcare community, while facilitating optimal utilization of resources and cost-effective practices for RSV prophylaxis in Qatar. It also acknowledges the necessity to collaborate with other GCC countries and develop a regional protocol to further strengthen the RSV prevention efforts."

Journal • Review • Critical care • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis. (PubMed, Front Pediatr) - "Compared with the placebo, nirsevimab, motavizumab, and palivizumab have shown beneficial effects at reducing RSV-related hospitalization rates (RR, nirsevimab: 0.20, 95% CI: 0.09-0.45; motavizumab: 0.32 95% CI: 0.19-0.53; palivizumab: 0.43; 95% CI: 0.30-0.61) and Intensive Care Unit (ICU) admissions due to RSV infections (nirsevimab: 0.09, 95% CI: 0.01-0.87; motavizumab: 0.23, 95% CI: 0.08-0.65; palivizumab: 0.43, 95% CI: 0.21-0.90) in preterm infants. However, further studies are needed to confirm these findings. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024583222, identifier CRD42024583222."

Journal • Retrospective data • Review • Critical care • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia. (PubMed, Infect Dis Ther) - "Nirsevimab was associated with larger reductions in RSV-related events, greater reductions in event-related costs, and higher QALYs than SoC and RSVpreF. Its adoption in national immunization programs could significantly reduce the economic and disease burden of RSV and improve infant health."

Journal • Critical care • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case-control study. (PubMed, Lancet Child Adolesc Health) - P | "In the real-world setting of the UK's maternal vaccination programme, RSVpreF vaccination was effective up until the age of 6 months in reducing the risk of hospital admission with RSV-associated ALRI, as was the UK's infant RSV prevention programme. These data could help decision makers to evaluate whether RSVpreF or an anti-RSV infant monoclonal antibody best serves the needs of their infant population."

Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection trial. (PubMed, NPJ Drug Discov) - P2 | "Intranasal palivizumab does not protect against RSV infection under optimally controlled conditions. Intranasal mAbs are highly unlikely to be a feasible and cost-effective method of protection against respiratory infection."

Clinical • Journal • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness. (PubMed, Hum Vaccin Immunother) - "For decades, prophylaxis was limited to monthly palivizumab for selected high-risk infants...Across 43 observational studies, pooled effectiveness against RSV-associated hospitalization was 80.9% for nirsevimab and 79.1% for maternal RSVpreF vaccination, demonstrating substantial real-world protection during early infancy. Success now depends on optimizing implementation and achieving equitable access."

Clinical • Journal • Real-world evidence • Retrospective data • Review • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Advances in respiratory syncytial virus therapeutics: A comprehensive review of small-molecule inhibitors, monoclonal antibodies, and vaccines. (PubMed, Eur J Med Chem) - "Despite the clinical use of ribavirin and the monoclonal antibody palivizumab, their limitations in efficacy, safety, and cost necessitate the development of novel anti-RSV agents. Key challenges such as drug resistance, target specificity, and patient heterogeneity are addressed, and future directions-including structure-based drug design, host-targeted therapies, drug repurposing, and combination strategies-are proposed. This review aims to provide medicinal chemists with a structured update on RSV drug discovery and to accelerate the development of effective antiviral strategies."

Journal • Review • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

RESPIRIAMO - Italian hospital surveillance for lower respiratory tract infections: a multicenter retrospective cohort study of respiratory syncytial virus-associated hospitalizations in children under 2 years of age. (PubMed, BMC Pediatr) - "RSV was the predominant cause of LRTI and was associated with significantly greater disease severity. Most hospitalized infants were previously healthy, underscoring the need for preventive strategies targeting the general infant population."

Journal • Retrospective data • Critical care • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025. (PubMed, EClinicalMedicine) - "We searched PubMed, Scopus, and Web of Science for randomised controlled trials and observational studies published between January 1, 2018, and September 8, 2025, that evaluated palivizumab, nirsevimab, and RSV vaccines in infants, pregnant women, and older adults. Additionally, both maternal and older adult vaccinations are effective in reducing RSV-associated diseases. General Research Fund, AIR@InnoHK."

Journal • Retrospective data • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections